$VVOS

Vivos Therapeutics (VVOS) reported a threefold increase in referrals to its Las Vegas sleep centers, expecting Q4 revenue growth. The company targets $3.6M in annual savings by Q4 2026 and projects $1.5M-$3.0M from EEG initiatives, $3.5M from remote monitoring by Q1 2027, and $2.4M-$5.6M from payer contract renegotiations. Management aims for positive cash flow by late 2026 and profitability in 2027.

Vivos Therapeutics, Inc. (VVOS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. As previously reported, Vivos Therapeutics, Inc. (the “Company”) previously sold and issued to Streeterville Capital, LLC, a Utah limited liability company (“Streeterville”), a Secured Promissory Note with an original issuance

Vivos Therapeutics (VVOS) partners with South Palm Cardiovascular Associates to establish a Sleep & Airway Medicine Center in Florida. Vivos will hold 75% of the new entity, AIM Florida, with plans to start operations in Q1 2027. The center aims to treat 250 patients monthly, generating up to $6M annual revenue with 30%+ margins. SPCVA will expand referrals for sleep disorder-related conditions. VVOS stock is currently at $0.25, up 0.58%.

Vivos Therapeutics (NASDAQ:VVOS) said the U.S. Patent and Trademark Office issued U.S. Patent No. 12,697,190, a continuation of a 2024 patent, to broaden IP protection for its Vivos CARE oral device technology for obstructive sleep apnea. The company says the layered patents are harder for competitors to design around and support its FDA-cleared devices for severe adult and pediatric OSA.

Vivos Therapeutics, Inc. (VVOS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. The information set forth under Item 5.02 of this Current Report on Form 8-K regarding the Separation, Resignation and Executive Transition Agreement, dated as of July 31, 2026 (the “ Separation Agreement ”), between Vivos Th

Vivos Therapeutics, Inc. (VVOS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 5 ex10-1.htm EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “ Agreement ”) is dated as of June [_], 2026, between Vivos Therapeutics, Inc., a Delaware corporation (the “ Company ”), and each purchaser identified on the signatur

Vivos Therapeutics (NASDAQ: VVOS) reported single-site clinical study results for its FDA-cleared Vida oral appliance in 37 adults with moderate-to-severe insomnia. All participants improved at least one Insomnia Severity Index category; average ISI fell ~65% and all ended as no clinically significant or subthreshold insomnia (p~1e-7). Vivos cites potential market expansion beyond OSA/COMISA.

Vivos Therapeutics, Inc. (VVOS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. false 0001716166 0001716166 2026-06-25 2026-06-25 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Repor

Vivos Therapeutics, Inc. (VVOS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 ex10-1.htm EX-10.1 Exhibit 10.1 COLLABORATION AGREEMENT This Collaboration Agreement (this “ Agreement ”) is entered into as of June 9, 2026 (the “ Effective Date ”), by and between Vivos Therapeutics, Inc. , a Delaware corporation with principal offices at 7921 Southpa

Vivos Therapeutics (VVOS) said it will collaborate with South Palm Cardiovascular Associates (SPCVA) to form AIM Florida, LLC, a physician-aligned management services organization to expand integrated diagnosis and treatment for obstructive sleep apnea and insomnia in cardiovascular disease patients. Vivos expects to hold at least 80% of AIM Florida. The initial focus is Palm Beach County.